Comprehensive assessment of homologous recombination deficiency via simultaneous methylation and mutation analysis in epithelial ovarian cancer: implications for PARP inhibitors efficacy
Our findings underscore the importance of considering HRD etiology when evaluating PARPi efficacy in EOC patients. The GM-seq pipeline, represents a significant advancement in HRD detection, enabling more accurate predictions of PARPi response.
Authors
- Xin Yi (ORCID: https://orcid.org/0000-0003-4032-0298)
- Jianming Ying (ORCID: https://orcid.org/0000-0003-2692-4052)
- Huanwen Wu (ORCID: https://orcid.org/0000-0002-3996-3176)
- Huan Yin (ORCID: https://orcid.org/0009-0001-0800-8651)
- Dong Lin (ORCID: https://orcid.org/0000-0002-1196-2446)
- Wenbin Li (ORCID: https://orcid.org/0000-0003-0828-379X)
- Ning Li (ORCID: https://orcid.org/0000-0003-3175-8343)
- Rongrong Chen (ORCID: https://orcid.org/0000-0002-5362-2116)
- Jie Huang (ORCID: https://orcid.org/0000-0003-2096-8556)
- Yan Song (ORCID: https://orcid.org/0000-0001-8554-2703)
- Huan Fang (ORCID: https://orcid.org/0000-0003-1306-1358)
- Yuanyuan Xiong
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- National Cancer Center (US)
- National Institutes for Food and Drug Control (CN)
Publication Details
- Journal
- Biomarker Research
- Published
- 2025-10-10
- DOI
- https://doi.org/10.1186/s40364-025-00843-6
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Beijing Xisike Clinical Oncology Research Foundation
- Chinese Society of Clinical Oncology